Astria Therapeutics

Omega Therapeutics (NASDAQ: OMGA) Stock Quote Follow

Last Trade: US$6.87 0.36 5.53
Volume: 43,908
5-Day Change: -12.04%
YTD Change: 20.32%
Market Cap: US$330.100M

Latest News From Omega Therapeutics

March 1, 2023
Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Advanced Company’s Lead Program, OTX-2002, in the Clinic; Preliminary Data from Phase 1/2 MYCHELANGELO™ I Trial Anticipated in 2023 Progressed IND-enabling Studies for OTX-2101; Company’s Development Candidate for MYC-driven Non-Small Cell Lung Cancer to Utilize a Novel Lung-Targeting Lipid Nanoparticle Ended the Year with Cash, Cash Equivalents and Marketable Securities of $124.7 Million as of December 31, 2022 Further... Read More
February 23, 2023
Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock
CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 6,920,415 shares of common stock (the “Shares”) at a purchase price of $5.78... Read More
January 17, 2023
Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it will present a trial-in-progress poster at the upcoming American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco,... Read More
October 27, 2022
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
OTX-2002 is the First-Ever Epigenomic Controller in a New Class of Programmable mRNA Therapeutics to be Administered to Patients Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines, today announced dosing of the first patient in its Phase 1/2 MYCHELANGELO ™ I trial evaluating OTX-2002... Read More
October 12, 2022
Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer
OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced that it has selected... Read More
September 26, 2022
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced that members of management will participate in two upcoming investor conferences. Jefferies Cell and Genetic Medicine Summit Fireside Chat Date:... Read More
September 6, 2022
Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced that management will participate in a fireside chat at the H.C. Wainwright 24 th Annual Global Investment Conference on Monday, September 12, 2022... Read More
September 1, 2022
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors
Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent... Read More
August 4, 2022
Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
FDA Clearance of IND Application for OTX-2002, the First Ever Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma Received Launch of Phase 1/2 Clinical Trial Under the MYCHELANGELO TM Clinical Program in Patients Expected in 2H'22 Data from Preclinical Studies Show Promising Anti-Tumor Activity and Loss of Cancer Cell Viability Achieved Through Pre-Transcriptional Downregulation of MYC Gene Expression $173.7... Read More
August 3, 2022
Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Thomas McCauley , Chief Scientific Officer, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022 , at 8... Read More
July 14, 2022
Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
Represents First Ever Epigenomic Controller, a New Class of Programmable mRNA Therapeutics, to Receive IND Clearance Phase 1/2 Clinical Trial Expected to Launch in 2H'22 and Will Evaluate the Safety and Preliminary Antitumor Activity of OTX-2002 Omega Therapeutics, Inc. ( Nasdaq : OMGA ) ("Omega"), today announced that it has received clearance of its Investigational New Drug ( IND ) application from the U.S. Food and Drug... Read More
June 30, 2022
Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer
Treatment with epigenomic controller, OTX-2002, resulted in robust in vivo efficacy in xenograft tumor models OTX-2002 successfully achieved pre-transcriptional downregulation of hepatocyte MYC gene expression in non-human primates Clinical potential of OTX-2002 as a monotherapy or in combination with existing standard-of-care therapies, including immune checkpoint inhibitors IND filed by the company to advance OTX-2002 into... Read More
June 23, 2022
Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that it will present preclinical data for OTX-2002, the Company's lead candidate for the treatment of hepatocellular carcinoma (HCC), at the... Read More
June 15, 2022
Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
Investigational New Drug Application Submitted by Omega Represents the First Epigenomic Controller in a New Class of Programmable mRNA Therapeutics Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega") today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, OTX-2002, for the treatment of hepatocellular carcinoma... Read More
June 2, 2022
Omega Therapeutics to Participate in the Jefferies Healthcare Conference and Goldman Sachs 43rd Annual Global Healthcare Conference in June 2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Mahesh Karande , President and CEO, will participate in fireside chats at the following upcoming investor conferences in June. Jefferies Healthcare... Read More
May 4, 2022
Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Investigational New Drug Application for OTX-2002 for MYC Driven Hepatocellular Carcinoma on Track to be Submitted in the First Half of 2022 Additional Omega Epigenomic Controller™ Development Candidates on Track to be Nominated in the Middle of 2022 $200.8 Million in Cash, Cash Equivalents and Marketable Securities at End of First Quarter Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology... Read More
HealthStocksHub
May 3, 2022
Omega Therapeutics to Unveil Preclinical Data on Epigenomic Programming of MYC with Epigenomic Controllers as a Promising Therapeutic Approach in Non-Small Cell Lung Cancer at the 25th Annual ASGCT...
Regulation of MYC gene expression via epigenomic programming results in decreased viability of cancer cells in vitro and reduced tumor burden in in vivo xenograft models Data demonstrate potential of Omega Epigenomic Controllers (OEC) to be developed as standalone therapy or in combination with standard of care therapies in... Read More
HealthStocksHub
April 29, 2022
Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer
Roger Sawhney , M.D. to serve as Chief Business Officer Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today... Read More
HealthStocksHub
April 8, 2022
Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022
OTX-2002 suppresses c-Myc gene expression resulting in a loss of cancer cell viability in vitro and reduces tumor growth in in vivo xenograft models Data support the potential of the OMEGA Epigenomic Programming™ platform to engineer programmable epigenetic mRNA therapeutics that successfully regulate gene expression Robust... Read More
March 30, 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Kevin McManus Appointed as Chief Human Resources Officer Ling Zeng, Esq. , Appointed as Chief Legal and Administrative Officer Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines through its OMEGA Epigenomic Programing™ platform, today announced the appointment of... Read More
HealthStocksHub
March 10, 2022
Omega Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Outlines Key Corporate Objectives for 2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced financial results for the fourth quarter... Read More
HealthStocksHub
March 8, 2022
Omega Therapeutics to Present Preclinical Data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing ™ platform, today announced that it will present preclinical data for... Read More
HealthStocksHub
January 10, 2022
Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Yan Moore , M.D., as... Read More
HealthStocksHub
November 18, 2021
Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing ™ platform, today announced that Mahesh Karande , President and Chief... Read More
HealthStocksHub
November 10, 2021
Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corporate Objectives
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the third quarter... Read More
HealthStocksHub
November 9, 2021
Omega Therapeutics to Present at the Jefferies London Healthcare Conference
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Mahesh Karande , President and Chief... Read More
HealthStocksHub
October 14, 2021
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the... Read More
HealthStocksHub
September 27, 2021
Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Mahesh Karande , President and Chief Executive... Read More
HealthStocksHub
September 10, 2021
Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the second quarter ended June 30,... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB